What drives the decision to optimise biological treatment in children and youngsters with juvenile idiopathic arthritis? A discrete-choice experiment.
Murias S, Boteanu A, Calvo I, Nuñez E, Bravo B, Bustabad S, Camacho M, Clemente D, Graña J, de Inocencio J, Lacruz L, Mesa-Del-Castillo P, Nieto-González JC, Pinedo MDC, Quesada E, Vargas C, Antón J.
Murias S, et al.
Reumatol Clin (Engl Ed). 2023 Jan;19(1):26-33. doi: 10.1016/j.reumae.2022.11.002.
Reumatol Clin (Engl Ed). 2023.
PMID: 36603964
Free article.
The presence of macrophage activation syndrome (MAS), systemic involvement, or subclinical inflammation made the decision easier (highest weights). The presence of joints of difficult control and year of debut influenced the decision in some but not all, and in different d …
The presence of macrophage activation syndrome (MAS), systemic involvement, or subclinical inflammation made the decision easier (highest we …